Vitality Watch

Dossier pubmed review 21-sep-2026
Narrative review or expert overview without new data

Orchestrating Stress Granule Dynamics by SUMOylation: A New Frontier in Treating Stress-Induced Age-Related Diseases.

Key claim: SUMOylation orchestrates stress-granule nucleation and disassembly, and correcting SUMO–SG pathway imbalance may restore proteostasis and healthspan in stress-associated age-related diseases.

Abstract

Stress granules (SGs), membrane-less organelles formed via liquid-liquid phase separation (LLPS), function as essential adaptive compartments that sequester mRNAs and proteins during acute stress. However, during chronic stress or aging, these dynamic condensates can undergo an irreversible phase transition into pathological insoluble aggregates, driving neurodegeneration and metabolic decline. The pivotal role of SUMOylation is elucidated as a molecular switch orchestrating the SG life cycle, from rapid nucleation and component recruitment to timely disassembly. The multivalent engagement of SUMO proteins and SUMO-interacting motifs (SIMs) is discussed as a biochemical glue that lowers the kinetic threshold for LLPS and maintains the fluid-like state of SG scaffold proteins. Furthermore, the dysregulation of the SUMO pathway, particularly the imbalance between E3 ligases and deSUMOylating enzymes, is examined in the context of cellular senescence, neurodegenerative proteinopathies, reproductive aging, and musculoskeletal degeneration. Emerging therapeutic strategies targeting the SUMO-SG axis are evaluated, including the clinical-stage inhibitor TAK-981, selective SUMO-specific proteases modulators such as Momordin Ic, and multi-target natural products. By decoding how the SUMO code biophysically governs cellular resilience, this review highlights the potential of state-corrective interventions to restore proteostasis and extend healthspan in stress-associated aging disorders.

Why this matters

Stress granules and SUMOylation have both been proposed independently as aging-relevant proteostasis nodes; this review joins them by framing SUMO as the biophysical switch that determines whether SGs stay reversible or solidify into pathological aggregates. That framing turns SUMO E1/E2/E3 and SENP enzymes — plus a growing catalog of SUMO-pathway drugs — into candidate levers on the SG life cycle, though every claim here is mechanism-plausible synthesis rather than an outcome study.

Source

Link

Briefing card

Orchestrating Stress Granule Dynamics by SUMOylation: A New Frontier in Treating Stress-Induced Age-Related Diseases.
Stage: review · pubmed · 21-sep-2026

If you're tracking SUMO-pathway drugs like TAK-981 as potential geroprotectors, this is still mechanism-level reasoning about stress granules — no human aging outcomes have been measured.

SUMOylation orchestrates stress-granule nucleation and disassembly, and correcting SUMO–SG pathway imbalance may restore proteostasis and healthspan in stress-associated age-related diseases.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.phrs.2026.108464

build build 880 · 2bcef25 · 2026-11-18